Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups-Reference-Cited by-同舟云学术

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

Published:2018-09-28 Issue:2 Volume:12 Page:151-163
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Li Jianguo¹,Lovern Mark²,Green Michelle L.²,Chiu Joannellyn²,Zhou Diansong¹,Comisar Craig²,Xiong Yuan²,Hing Jeremy²,MacPherson Merran³,Wright James G.³,Riccobene Todd⁴,Carrothers Timothy J.⁴,Das Shampa⁵

Affiliation:

1. AstraZeneca Waltham Massachusetts USA

2. Quantitative Solutions Raleigh North Carolina USA

3. Wright Dose Ltd Altrincham Cheshire UK

4. Allergan PLC Madison New Jersey USA

5. AstraZeneca Alderley Park Macclesfield UK

Funder

AstraZeneca

Pfizer

Forest Laboratories

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12585

Reference50 articles.

1. Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action

2. Hospital-acquired pneumonia and ventilator-associated pneumonia

3. Urinary Tract Infection

4. Complicated intra-abdominal infections in a worldwide context: an observational prospective study (CIAOW Study)

5. Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria;International Journal of Antimicrobial Agents;2024-09

2. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients;Journal of Antimicrobial Chemotherapy;2024-08-19

3. Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic Modelling;Antibiotics;2024-08-11

4. Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study;Infection and Drug Resistance;2024-07

5. Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae;Journal of Infection and Public Health;2024-05